Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases
Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases
复制标题
DOI：
10.1038/bjc.1998.627
复制
发表时间：
1998-10-01
影响因子：
8.8
通讯作者：
Allen-Mersh, TG
中科院分区：
文献类型：
--
作者：
Fordy, C;Glover, C;Allen-Mersh, TG
在35例全身性氟尿嘧啶/亚叶酸耐药的结直肠肝转移患者中，肝动脉尿嘧啶核苷（HAI）达到了14%的部分缓解率和26%的疾病稳定率，自HAI发作起的中位缓解持续时间为7个月。
Hepatic arterial floxuridine (HAI) in 35 patients with systemic fluorouracil/folinic acid-resistant colorectal liver metastases achieved a 14% partial response and 26% disease stabilization rate, with a median response duration of 7 months from onset of HAI.